Network Bio is a technology company.
Network Bio has raised $20.0M across 2 funding rounds.
Network Bio has raised $20.0M in total across 2 funding rounds.
Network Bio has raised $20.0M in total across 2 funding rounds.
Network Bio's investors include Array Ventures, Stuart Peterson, Artis Ventures (AV), Founders Fund, Gradient Ventures, Kickstart Fund, Thiel Capital, Transformation Capital, Trucks Venture Capital, Conor Bronsdon, Doug Hayes, Hari Lakshmanan.
Network Bio is a seed-stage technology company founded in 2023 and headquartered in Austin, Texas, that builds a platform for securitizing biomedical data to advance precision medicine.[1][2][4] It serves healthcare institutions and biomedical researchers by enabling the creation of research-grade data assets through biobanking infrastructure, sponsored sequencing, data analytics, and operational workflows from sample collection to informatics, addressing capital and resourcing constraints in biobanks.[1][2] The platform facilitates medical collaborations, invests in biobanking operations, and drives measurable progress in therapeutic areas by providing world-class data for AI-enabled biomedical innovation.[2][4]
With $19.5M in total seed funding, including a $17M round on February 27, 2025, led by Founders Fund, S32, Artis Ventures, Breyer Capital, and Fundomo, Network Bio shows strong early momentum in the bioinformatics and precision medicine space.[4]
Network Bio was founded in 2023 by Asad Ali Ahmad and Raphael Potter, emerging amid growing demand for high-quality biomedical data to fuel AI-driven precision medicine.[1][4] The idea stems from recognizing biobanks as the next frontier in healthcare, where institutions face capital shortages and operational hurdles in activating dormant biological samples for research.[2] Early traction came through its innovative securitization model, which infuses capital, operators, and top researchers to transform biobanks into productive assets, quickly attracting high-profile seed investors and positioning the company for rapid scaling.[2][4]
Network Bio rides the wave of AI-enabled precision medicine, where demand for vast, high-quality biomedical datasets is exploding to train models for drug discovery, personalized treatments, and cellular reprogramming.[2][3] Timing is ideal post-2023, as biobanks—long underutilized due to funding gaps—align with surging investments in biotech AI, evidenced by peers like Engine Biosciences pioneering network biomedicine.[3] Market forces like rising healthcare data needs, regulatory pushes for real-world evidence, and VC influx into life sciences (e.g., its own $19.5M seed) favor it, while influencing the ecosystem by democratizing access to securitized data assets and accelerating progress in key therapeutic areas.[2][4]
Network Bio is poised to expand its securitization platform, likely pursuing Series A funding and strategic partnerships with major biobanks to scale data asset creation amid booming AI-biotech convergence.[2][4] Trends like multimodal AI integration in drug development and global precision medicine adoption will propel it, potentially evolving its influence from niche enabler to central hub for research-grade biomedical data. As biobanks become precision medicine's backbone, Network Bio's model positions it to unlock trillions in latent value, transforming healthcare innovation from the ground up.[2]
Network Bio has raised $20.0M across 2 funding rounds. Most recently, it raised $17.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $17.0M Seed | Array Ventures, Stuart Peterson, Artis Ventures (AV), Founders Fund, Gradient Ventures, Kickstart Fund, Thiel Capital, Transformation Capital, Trucks Venture Capital, Conor Bronsdon, Doug Hayes, Hari Lakshmanan, Immad Akhund, Kenan Turnacioglu | |
| Aug 1, 2022 | $3.0M Seed | Array Ventures, Artis Ventures (AV), Gradient Ventures, Kickstart Fund, Transformation Capital, Trucks Venture Capital, Conor Bronsdon, Doug Hayes, Hari Lakshmanan, Immad Akhund |